<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5445C71-1B27-48E2-A67A-03B3384FD1EE"><gtr:id>A5445C71-1B27-48E2-A67A-03B3384FD1EE</gtr:id><gtr:name>The Office for Creative Research (OCR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/13F70662-CB09-4DCE-94F5-CEDE5C696FAE"><gtr:id>13F70662-CB09-4DCE-94F5-CEDE5C696FAE</gtr:id><gtr:name>The European League Against Rheumatism (EULAR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB96C24E-6EF5-42B1-9EC8-CEE2C6BF4806"><gtr:id>AB96C24E-6EF5-42B1-9EC8-CEE2C6BF4806</gtr:id><gtr:name>uMotif</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC2603FA-F836-461F-ABD5-FE3A55A78A6C"><gtr:id>EC2603FA-F836-461F-ABD5-FE3A55A78A6C</gtr:id><gtr:name>Health Unlocked</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC177B1F-35EE-4B74-981D-E8382EE3D18C"><gtr:id>EC177B1F-35EE-4B74-981D-E8382EE3D18C</gtr:id><gtr:name>London School of Economics &amp; Pol Sci</gtr:name><gtr:address><gtr:line1>Houghton Street</gtr:line1><gtr:line2>Aldwych</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>WC2A 2AE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5445C71-1B27-48E2-A67A-03B3384FD1EE"><gtr:id>A5445C71-1B27-48E2-A67A-03B3384FD1EE</gtr:id><gtr:name>The Office for Creative Research (OCR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/13F70662-CB09-4DCE-94F5-CEDE5C696FAE"><gtr:id>13F70662-CB09-4DCE-94F5-CEDE5C696FAE</gtr:id><gtr:name>The European League Against Rheumatism (EULAR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB96C24E-6EF5-42B1-9EC8-CEE2C6BF4806"><gtr:id>AB96C24E-6EF5-42B1-9EC8-CEE2C6BF4806</gtr:id><gtr:name>uMotif</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC2603FA-F836-461F-ABD5-FE3A55A78A6C"><gtr:id>EC2603FA-F836-461F-ABD5-FE3A55A78A6C</gtr:id><gtr:name>Health Unlocked</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC177B1F-35EE-4B74-981D-E8382EE3D18C"><gtr:id>EC177B1F-35EE-4B74-981D-E8382EE3D18C</gtr:id><gtr:name>London School of Economics &amp; Pol Sci</gtr:name><gtr:address><gtr:line1>Houghton Street</gtr:line1><gtr:line2>Aldwych</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>WC2A 2AE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D6E2F2F4-94A8-4F09-B09B-2D1E8AC982C6"><gtr:id>D6E2F2F4-94A8-4F09-B09B-2D1E8AC982C6</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Gregory</gtr:otherNames><gtr:surname>Dixon</gtr:surname><gtr:orcidId>0000-0001-5881-4857</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902272"><gtr:id>3A23A44C-A9E1-48EB-AB3D-C29E23670D5F</gtr:id><gtr:title>The safety of glucocorticoids in patients with inflammatory musculoskeletal conditions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902272</gtr:grantReference><gtr:abstractText>Glucocorticoids, also known as steroids, are drugs commonly used for the treatment of rheumatoid arthritis and other inflammatory conditions. Steroids are a good treatment because they quickly ease joint pain, swelling and stiffness, thus improving disability. However, as with most medication, there are potential side effects. 

When starting medication, most patients want to know their chance of developing side effects. However, we don?t know accurately how commonly side effects occur, what dose of steroid leads to side effects, or what sort of person is particularly at risk. The chance of side effects probably varies according to many factors, including how old a patient is, their gender, whether they have other diseases, or are taking other medication. This research aims to answer these questions, and to provide a likelihood of side effects tailored to the individual.

Only patients themselves know whether they take their medicines, at what dose, or whether they develop side effects. In order to improve risk measurement, we need to collect such information directly from patients. Then, having measured risk, we need to improve the way we communicate this information to patients. This project aims to develop electronic systems to advance this two-way communication.</gtr:abstractText><gtr:technicalSummary>Aim 
 To quantify the risk of single and multiple adverse events in patients with inflammatory musculoskeletal conditions treated with glucocorticoid (GC) therapy. 
Objectives
 To explore the association between time-varying GC dosage and route of administration of GC and outcome.
 To develop and validate a predictive tool to estimate likelihood of GC-associated adverse events.
 To address the influence of adherence upon risk estimates.
 To better understand the benefit/ harm balance of GC use.
 To improve risk communication through development of an electronic visual tool
Design and Methodology
The planned analyses will use databases that are established or in development. First, nested case-control and cohort studies, with modelling of time-varying GC exposure including dose, will be undertaken using respected UK primary care databases: the General Practice Research Database and The Health Improvement Network. Prediction modelling will be used to identify patients at risk of GC-associated adverse events (including infection, cardiovascular disease, diabetes, fractures), in one dataset with validation in the second dataset. In order to address the influence of factors captured only in secondary care, such as parenteral GC therapy and disease severity measures, further analysis will be undertaken in two additional databases under development, the arc Early Inflammatory Arthritis Information System and the NorthWest e-Health e-Labs project. Additional funding will be sought to develop and implement novel technology to capture patient reported outcome measures and adherence data, and to develop an electronic visual tool for risk communication. 
Scientific and medical opportunities
It is not clear which GC treatment regimes place patients at risk of adverse events, what degree of risk is conferred, or what predisposes patients to such events. This makes accurate communication of risk difficult. The work described above will unpick some of the complexities of GC-associated adverse events. It will also move risk estimation towards personalised risk assessment, whereby patients can be informed of their individual risk of side effects given their profile, including demographics, disease characteristics and co-morbidity. 
Pharmacoepidemiology is currently limited by the scope of available datasets. These projects will improve capture of clinical data, both from clinicians and directly from patients. Although focussed on GC safety, the skills, techniques and visual tools developed in these projects will have wider application for investigating the safety of other medications.</gtr:technicalSummary><gtr:fund><gtr:end>2015-10-26</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1084091</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>This innovative arts-science collaboration allowed visual artist Nicola Dale to undertake a residency in the Arthritis Research UK Centre for Epidemiology (CfE) that was founded in 1954. The initial aim was to research, develop and create artworks inspired by the CfE's archive, and to reflect the relevance of the archive in today's medical and epidemiological practice. Nicola focussed on an x-ray archive collected by the first Director, Dr John Lawrence, in a 1950's study of rheumatism in local miners. 

Further supported by a Wellcome Trust ISSF Public Engagement Award, the work extended to include interviews and workshops with patients and local miners in collaboration with the Centre for History of Science, Technology &amp;amp; Medicine. Local miners were invited through a live discussion on BBC Radio Manchester. These interviews significantly influenced several art pieces. A further collaboration with the Granada Centre for Visual Anthropology allowed students to document the project through short films, shown in the final exhibition.

The project was conceived to make epidemiology accessible through a creative collaboration interweaving art, history, science and medicine.</gtr:description><gtr:id>860E237C-9943-47D2-896B-396EF63EA77E</gtr:id><gtr:impact>The work culminated with a public exhibition &amp;quot;Bedrock&amp;quot; in Salford from 28-31st January that featured 
sculptures and 2-D artwork, an artist's talk as well as films of the creative process and an uncovered 1952 film of Dr Lawrence at the Walkden Miners Clinic from the BFI archive. The exhibition had significant press interest including the BBC and Manchester Evening News. There were 188 visitors over three days including members of the public, arthritis patients, miners, artists, MA students from the Granada Centre, clinicians and UoM researchers. During the show there were 1052 visitors to www.nicoladale.com. Visitor book comments included:
&amp;quot;Such a well researched project and so painstakingly, imaginatively and beautifully executed&amp;quot;
&amp;quot;An epic subject well deserving the epic exposition.&amp;quot;
&amp;quot;Moving, insightful, reflective, poetic. Wonderful collaboration between Nicola, Manchester University and a range of audiences.&amp;quot; 
Nicola has maintained a project blog and is producing a commemorative publication. 

In addition to the exhibition, further engagement and impact included visits to the artist's studio for the research group, encouraging their own involvement in traditional and creative public engagement. 

The project has an important legacy in the artwork to be mounted in the CfE and within outpatients at Salford Royal Hospital. The work will also be showcased during the European City of Science Festival (July 2016) and will be included in the Manchester Histories Festival (June 2016).</gtr:impact><gtr:outcomeId>56cb86c443b814.82087998</gtr:outcomeId><gtr:title>Bedrock: Exhibition of Nicola Dale's artist-in-residence time in the Centre for Epidemiology</gtr:title><gtr:type>Artwork</gtr:type><gtr:url>http://www.nicoladale.com/bedrock---work-in-progress.html</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Office for Creative Research (OCR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>The Office for Creative Research</gtr:description><gtr:id>9C2CD80F-D63C-4181-A54A-6A17C2810B9F</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>5653b2b0650989.70864516-1</gtr:outcomeId><gtr:partnerContribution>Developing data visualisations and citizen science project</gtr:partnerContribution><gtr:piContribution>Established connection with OCR in 2015 to explore opportunities for collaboration around Cloudy with a Chance of Pain and implementation of Dynamic Consent interface</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Computer Science</gtr:department><gtr:description>Anna Cox</gtr:description><gtr:id>452D0DA0-51E3-4887-9448-4E94BF7CCA2E</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>5653b480266537.59156391-1</gtr:outcomeId><gtr:partnerContribution>Contribution to design and evaluation of Citizen Science experiment</gtr:partnerContribution><gtr:piContribution>Connection made with research group interested in studying Citizen Science projects</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Epidemiology, Biostatistics and Occupational Health</gtr:department><gtr:description>Michal Abrahamowicz</gtr:description><gtr:id>EBC17199-38FC-4AF8-8C2F-E5B0AB0337D3</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>h6ejeSk5jC5-1</gtr:outcomeId><gtr:partnerContribution>Biostatistical solutions to clinical and epidemiological challenges</gtr:partnerContribution><gtr:piContribution>Input of clinical and epidemiological challenges that require biostatistical solutions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The European League Against Rheumatism (EULAR)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EULAR Registers and Observational Drug Studies (RODS)</gtr:description><gtr:id>7A71F140-4108-44E4-870B-86E9D235E5DB</gtr:id><gtr:impact>Inaugural meeting of RODS
Working Groups in progress</gtr:impact><gtr:outcomeId>J6KL6fX1TMv-1</gtr:outcomeId><gtr:partnerContribution>Community of registers and observational drug studies across European rheumatology. Inaugural meeting (convened by me) in Prague Nov 14/15th 2013</gtr:partnerContribution><gtr:piContribution>Co-Lead of EULAR RODS Study Group</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>uMotif</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>uMotif</gtr:description><gtr:id>638E7641-EED9-44F1-BBF3-6F6C07A1C3F5</gtr:id><gtr:impact>MRC Confidence in Concept award
Funding for Cloudy with a Chance of Pain, extending work to linkage to wearable devices</gtr:impact><gtr:outcomeId>545964e36eeef9.67422677-1</gtr:outcomeId><gtr:partnerContribution>Use of their configurable smartphone application and supporting systems</gtr:partnerContribution><gtr:piContribution>Co-design of smartphone application to collect data on musculoskeletal disease, including use of accelerometer and GPS data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Economics and Political Science (University of London)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dynamic consent</gtr:description><gtr:id>2BB08B71-885A-456E-8FCA-B426C86DF9E2</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>54595f26074163.11790843-2</gtr:outcomeId><gtr:partnerContribution>Established the model of dynamic consent and its practical application through a RTSB award</gtr:partnerContribution><gtr:piContribution>Provided clinical setting for application of dymanic consent model</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dynamic consent</gtr:description><gtr:id>F1B5CBC1-DFE4-47E0-B4BE-922C5767C4B4</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>54595f26074163.11790843-1</gtr:outcomeId><gtr:partnerContribution>Established the model of dynamic consent and its practical application through a RTSB award</gtr:partnerContribution><gtr:piContribution>Provided clinical setting for application of dymanic consent model</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The European League Against Rheumatism (EULAR)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EULAR taskforce on steroid safety</gtr:description><gtr:id>849C212E-2009-4D95-BE00-B9217068898C</gtr:id><gtr:impact>Publication in draft</gtr:impact><gtr:outcomeId>54596419650799.32951368-1</gtr:outcomeId><gtr:partnerContribution>Contributed to guidelines for the use of steroids in inflammatory musculoskeletal disease</gtr:partnerContribution><gtr:piContribution>Contributed to guidelines for the use of steroids in inflammatory musculoskeletal disease</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Health Unlocked</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Health Unlocked</gtr:description><gtr:id>CC0F32EE-1967-455D-9224-3AC0A6894A94</gtr:id><gtr:impact>No outputs to date</gtr:impact><gtr:outcomeId>56cb81569fe137.47701225-1</gtr:outcomeId><gtr:partnerContribution>Data provision and extension of their HealthGraph</gtr:partnerContribution><gtr:piContribution>Surveys within HU platform. Analysis of narratives within HU communities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Epidemiology, Biostatistics and Occupational Health</gtr:department><gtr:description>Robyn Tamblyn</gtr:description><gtr:id>B273555D-37C8-476E-ABA3-1C7732DE2C62</gtr:id><gtr:impact>Publications in progress. Abstracts accepted at ISPE meeting</gtr:impact><gtr:outcomeId>iyitonsRMMe-1</gtr:outcomeId><gtr:partnerContribution>Co-applicant on international pharmacosurveillance project. Coordinated by Robyn Tamblyn @ McGill</gtr:partnerContribution><gtr:piContribution>Co-applicant on international pharmacosurveillance project. Run UK arm of three international sites</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Goran Nenadic</gtr:description><gtr:id>7F415F1E-103B-4B35-AF97-E912B3FD8947</gtr:id><gtr:impact>One publication to date</gtr:impact><gtr:outcomeId>56cb80cc88f7f7.70088075-1</gtr:outcomeId><gtr:partnerContribution>Computer Science methods to help solve epidemiological challenges</gtr:partnerContribution><gtr:piContribution>Collaborative working on multiple projects: automated deidentification of EPR letters, extracting dose information from prescriptions, narratives within HealthUnlocked</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Bedrock: Public exhibition of artwork from Centre for Epidemiology artist in residence</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F8F4435D-ACA4-4B28-8543-6BBFB5471930</gtr:id><gtr:impact>Three-day public exhibition &amp;quot;Bedrock&amp;quot; in Jan 2016, with BBC coverage (funded by the Wellcome Trust)
Legacy artwork to be mounted in Centre for Epidemiology &amp;amp; Salford Royal Hospital
Due to feature in Manchester Histories Festival June 2016 &amp;amp; European City of Science Festival 2016</gtr:impact><gtr:outcomeId>56cb85d37d2489.32958951</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nicoladale.com/uploads/1/0/3/6/10361696/ndale_uom_residency_info_2015.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National newspaper coverage</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E1138FF5-7D7C-470F-A41D-7FD6AD218587</gtr:id><gtr:impact>Articles about Cloudy with a Chance of Pain features in multiple national newspapers, both print and online editions. National papers included the Independent, The Mirror, Daily Express and Daily Mail.</gtr:impact><gtr:outcomeId>56e075b52976c6.38055953</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.independent.co.uk/life-style/health-and-families/health-news/smartphone-app-could-help-uncover-link-between-weather-and-chronic-pain-a6835686.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC2's Trust Me I'm a Doctor</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E7CDEC00-2241-480D-834A-A503029C6318</gtr:id><gtr:impact>Broadcast planned for January 2016. Should drive recruitment

Due to broadcast Jan 2016</gtr:impact><gtr:outcomeId>5653b3cdbb96c1.82071541</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Breakfast</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6235C235-1488-4EC7-8D84-854BD3439692</gtr:id><gtr:impact>Video feature and then interview on the 'BBC Breakfast couch'. Viewing figures of 7M. Significant public response following broadcast with recruitment spike of around 4000 new registrants that day. Recruiting one new user per second following the show</gtr:impact><gtr:outcomeId>56e073aa62dfc8.26501611</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>E-Health Centres of Excellence</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A6908138-F381-4119-BB02-0AD7E91D79B4</gtr:id><gtr:outcomeId>RmrEaMEupZV</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30182</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Granulomatosis with Polyangiitis: Defining the risk of infection associated with the disease and treatment, Arthritis Research UK</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>6425E24D-571C-4C62-B3AD-C97FD088A604</gtr:id><gtr:outcomeId>545960eabeaee1.96990906</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>269382</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>INBANK Project Manager &amp;amp; Project Support Officer</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>62E31B47-DCAB-4439-8C5B-6499C4104DCA</gtr:id><gtr:outcomeId>sVUKMWzEnRP0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cross-Farr small awards</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Farr Institute of Health Informatics Research</gtr:fundingOrg><gtr:id>96A4E13D-41E6-451E-9D73-047D0F356F9A</gtr:id><gtr:outcomeId>58a225451262a8.17735398</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53876</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>INBANK Scientific Lead (Research Funding Award)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>BA4AF99A-5492-4B8C-A7C0-BA50CEDE9670</gtr:id><gtr:outcomeId>kmu4y5U5i1a</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106270</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept 2</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>20938DC0-F392-4581-8E30-76D4F8412C0C</gtr:id><gtr:outcomeId>5459605ad2a1e2.14244673</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>618424</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HS&amp;amp;DR</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>A3C74DAD-BB39-4CD7-9860-295D216494D4</gtr:id><gtr:outcomeId>56cb841face218.20681300</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>43416</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Salford EPR for research</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Salford Royal NHS Foundation Trust</gtr:fundingOrg><gtr:id>4138405A-94BF-430B-A950-257E55CE3AA1</gtr:id><gtr:outcomeId>QdwYTPawLpv</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>165670</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant: Psoriasis in UK BIobank</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>05F51EB9-D6A4-4183-8D10-6D188ED33D8F</gtr:id><gtr:outcomeId>56cb83e33dd350.23444376</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>394000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Special Strategic Award: REMORA</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>08182239-FEF7-431A-AF83-AD7D52ECF2AC</gtr:id><gtr:outcomeId>56cb83558794e4.19906283</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK Centre for Epidemiology</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>1F761A9B-FBBA-4553-ABCA-43445C4DF81E</gtr:id><gtr:outcomeId>UkViX4dqPW8</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3450</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ISSF</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8526470E-4B55-4366-8A22-88E1890546A2</gtr:id><gtr:outcomeId>56cb83071024b1.50817108</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>747000</gtr:amountPounds><gtr:country>Canada</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Evaluating the Accuracy of New Methods of Pharmacosurveillance: Computerized Administrative Data and Electronic Prescribing and Drug Management Systems</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Canadian Institutes of Health Research</gtr:fundingOrg><gtr:id>160426A9-68AD-4884-84C3-50B28C8D5098</gtr:id><gtr:outcomeId>q6kfsUv8rne0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Generic roll-out of the Arthritis Research UK Catalogue of Studies</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>4D0C381C-0AFD-4195-AC72-8C19CDB6F3F0</gtr:id><gtr:outcomeId>545960b12d2d93.97733415</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>199212</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Special Strategic Award: Cloudy with a Chance of Pain</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>3770427E-3A02-4C5D-8780-5DBC00A626FF</gtr:id><gtr:outcomeId>56cb82a48c2c72.62043080</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>249990</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant: Sleep-RA</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>C5D799A0-9941-4A1D-BAA6-8B5F69213406</gtr:id><gtr:outcomeId>56cb839fedc136.48721159</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EULAR taskforce on steroid safety</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>09412C12-7AED-4E4D-9FA9-F6654BFBB053</gtr:id><gtr:impact>Guidelines on the safe prescribing of glucocorticoid therapy will improve outcomes for patients treated with such therapies, avoiding unnecessary doses through guiding clinical practice</gtr:impact><gtr:outcomeId>58a22666b9beb4.05001448</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glucocorticoid infection risk included in UpToDate</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>86DFEB5F-A8A8-407D-92B4-6DBB0B64E9A8</gtr:id><gtr:outcomeId>tRy61tKgse9</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MHRA Ad Hoc Committee for the review of over the counter analgesics</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>78790D47-4F5C-44A5-A750-4FE1B5F2BFB7</gtr:id><gtr:impact>Improved balance of benefits and harms of prescribed over the counter medication</gtr:impact><gtr:outcomeId>54596214c18d09.81122379</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CHM Working Group on the safety and efficacy of insulins</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1FF15131-23EA-4527-A135-C5F5D16A3115</gtr:id><gtr:outcomeId>DxDfKsiaG7T</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2B2A1419-730F-4E0F-95AE-82A12ECA6FAD</gtr:id><gtr:title>Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7254db399794175604be2262869e8bd"><gtr:id>e7254db399794175604be2262869e8bd</gtr:id><gtr:otherNames>Strehl C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>58a222ae384da5.94232748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E94CBE58-8221-4CE6-9457-B32C1AD747D5</gtr:id><gtr:title>Looking beyond incidence in the relationship between anti-tumor necrosis factor therapy and malignancy.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>pm_13869_29_21305509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11ABCF55-A7A6-4F13-9CED-1989724A6A11</gtr:id><gtr:title>Modelling and extraction of variability in free-text medication prescriptions from an anonymised primary care electronic medical record research database.</gtr:title><gtr:parentPublicationTitle>BMC medical informatics and decision making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9946772801ba5ffbb80f838e4ba066f"><gtr:id>b9946772801ba5ffbb80f838e4ba066f</gtr:id><gtr:otherNames>Karystianis G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-6947</gtr:issn><gtr:outcomeId>56cb7e3ce328f6.39040684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>377AE8BC-1B67-4923-84D7-16194D1FB93A</gtr:id><gtr:title>Patient Perspectives on Sharing Anonymized Personal Health Data Using a Digital System for Dynamic Consent and Research Feedback: A Qualitative Study.</gtr:title><gtr:parentPublicationTitle>Journal of medical Internet research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b80a9b0fc72540bbf42f9a321b49e6f0"><gtr:id>b80a9b0fc72540bbf42f9a321b49e6f0</gtr:id><gtr:otherNames>Spencer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1438-8871</gtr:issn><gtr:outcomeId>585d68df80f284.70665130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F949E805-8350-4FF6-BFD0-61BB128EFE6A</gtr:id><gtr:title>Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd89c3abad19c0472cdedb8fed78261b"><gtr:id>dd89c3abad19c0472cdedb8fed78261b</gtr:id><gtr:otherNames>Galloway JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_22532633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A71D40B-CDD9-40AA-A6E9-62A2A5F30B6B</gtr:id><gtr:title>Who Self-Weighs and What Do They Gain From It? A Retrospective Comparison Between Smart Scale Users and the General Population in England.</gtr:title><gtr:parentPublicationTitle>Journal of medical Internet research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4e3437b92767d45591fd60fb5819eae"><gtr:id>b4e3437b92767d45591fd60fb5819eae</gtr:id><gtr:otherNames>Sperrin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1438-8871</gtr:issn><gtr:outcomeId>58a222aebb11c2.09393475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9874F9A0-EAB8-4CBB-86DF-10547631E8D4</gtr:id><gtr:title>Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4730225cd8cb5c9d48a0addd7c18360"><gtr:id>a4730225cd8cb5c9d48a0addd7c18360</gtr:id><gtr:otherNames>Costello R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5a2fd8aa25a567.09628728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43CF4CC8-A000-41A6-A2F4-DD5DE6182D4D</gtr:id><gtr:title>The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2af64503dc8b7cb1928b08b3556464bc"><gtr:id>2af64503dc8b7cb1928b08b3556464bc</gtr:id><gtr:otherNames>Kearsley-Fleet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>56cb7e3dac6585.01955915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58B71B07-94CE-4D62-A65F-8120531B2B03</gtr:id><gtr:title>Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/436a29d0a6a0bbb165e0802eaf6e975f"><gtr:id>436a29d0a6a0bbb165e0802eaf6e975f</gtr:id><gtr:otherNames>Low AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>58a222ade43c15.69740676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B96F574-8BC1-4374-93E2-1C014FE52753</gtr:id><gtr:title>Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c14caf910b5e81d4724320226bef57a"><gtr:id>3c14caf910b5e81d4724320226bef57a</gtr:id><gtr:otherNames>Humphreys JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a2fd75a4b4b84.90929224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6B9CAA9-A461-43B1-B9D1-003A17E5EE49</gtr:id><gtr:title>The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1fb87fcd35e0f57e8cbc96ade3f7db3"><gtr:id>d1fb87fcd35e0f57e8cbc96ade3f7db3</gtr:id><gtr:otherNames>Dixon WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>cCo7kRA4W1V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66B33C8C-4D9C-459D-8D75-55E4962673F5</gtr:id><gtr:title>Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>58a222adb3a4e4.26995602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C53EF6D0-97BE-44EF-9906-49A536C6402E</gtr:id><gtr:title>Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1fb87fcd35e0f57e8cbc96ade3f7db3"><gtr:id>d1fb87fcd35e0f57e8cbc96ade3f7db3</gtr:id><gtr:otherNames>Dixon WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_22241902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD7B3970-0298-4FB0-A280-CBC0036CF76E</gtr:id><gtr:title>A dynamic model of patient consent to sharing of medical record data.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1fb87fcd35e0f57e8cbc96ade3f7db3"><gtr:id>d1fb87fcd35e0f57e8cbc96ade3f7db3</gtr:id><gtr:otherNames>Dixon WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>54595c148ccb81.91038468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>575D38F9-3A29-4B6D-B114-D2230C8AF69B</gtr:id><gtr:title>Bisphosphonates and esophageal cancer--a pathway through the confusion.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1fb87fcd35e0f57e8cbc96ade3f7db3"><gtr:id>d1fb87fcd35e0f57e8cbc96ade3f7db3</gtr:id><gtr:otherNames>Dixon WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>DLAZFZpxaoD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CF40753-4C57-44C0-B910-F75B57CBC0DB</gtr:id><gtr:title>Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd89c3abad19c0472cdedb8fed78261b"><gtr:id>dd89c3abad19c0472cdedb8fed78261b</gtr:id><gtr:otherNames>Galloway JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>pm_13869_29_20675706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F207BDCC-472D-47C9-A2FD-F3ADA8ABFE6B</gtr:id><gtr:title>Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0eb6671bd663fafb56d65c9c30bad4ba"><gtr:id>0eb6671bd663fafb56d65c9c30bad4ba</gtr:id><gtr:otherNames>Gossec L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>56cb7e3e0b2974.74390075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BBC00A8-AF3E-4444-A4E6-758DC043C1F0</gtr:id><gtr:title>Problem list completeness in electronic health records: A multi-site study and assessment of success factors.</gtr:title><gtr:parentPublicationTitle>International journal of medical informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/528581c0ce8dcb110084d2672d1c43a4"><gtr:id>528581c0ce8dcb110084d2672d1c43a4</gtr:id><gtr:otherNames>Wright A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1386-5056</gtr:issn><gtr:outcomeId>56cb7e3d5090a6.06024864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F027B6E-46E6-4219-909C-38ED760497FD</gtr:id><gtr:title>Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd89c3abad19c0472cdedb8fed78261b"><gtr:id>dd89c3abad19c0472cdedb8fed78261b</gtr:id><gtr:otherNames>Galloway JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_21784730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA730D93-79B7-4773-AB25-86A1EB7777D7</gtr:id><gtr:title>The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_22241900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD77B137-8F9C-441E-B0D8-88F2B8606ABD</gtr:id><gtr:title>Half of U.K. patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8e571df0601bcdef6003f0de36363e7"><gtr:id>e8e571df0601bcdef6003f0de36363e7</gtr:id><gtr:otherNames>Black RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>56cb7e3e3916a8.95021115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0A98188-ABDE-4891-8EAE-50F96048E003</gtr:id><gtr:title>Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c37c3238c102c0027eabd2ff683cf06"><gtr:id>7c37c3238c102c0027eabd2ff683cf06</gtr:id><gtr:otherNames>Radner H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>56cb7e3d7f7d07.69837019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A250AB8-0AB9-4A0B-8711-C13F74B8AFAC</gtr:id><gtr:title>Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/714cf86530a1ae040bf0f71497a070cd"><gtr:id>714cf86530a1ae040bf0f71497a070cd</gtr:id><gtr:otherNames>Saketkoo LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn><gtr:outcomeId>56cb7e3e929f62.69923410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ACB0B56-7497-4915-B9F8-9904D999276E</gtr:id><gtr:title>Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0079ce09ac33715e4a1b52e10cec74b"><gtr:id>e0079ce09ac33715e4a1b52e10cec74b</gtr:id><gtr:otherNames>Solomon DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>pm_13869_29_23606026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E614F4D0-12FC-4B58-9286-DE5CF9DE2DBD</gtr:id><gtr:title>Influence of biological agents on cardiovascular disease in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88a962003faa20760bf3ce0f297a522a"><gtr:id>88a962003faa20760bf3ce0f297a522a</gtr:id><gtr:otherNames>Askling J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_21372192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68CDF571-9F14-4AB5-B120-FCB75BEA989A</gtr:id><gtr:title>Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>54595c1461e607.34550461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F066BE0A-55FC-421B-9430-D177396B659F</gtr:id><gtr:title>Rheumatoid arthritis: biological drugs and risk of infection</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5f7f996170128bc8bbefc87ec0be8d"><gtr:id>9a5f7f996170128bc8bbefc87ec0be8d</gtr:id><gtr:otherNames>Dixon W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56cb7e3dd7c316.91037522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81EA4286-D566-4DA4-B197-9A32CE447004</gtr:id><gtr:title>A comparison of methods for estimating the temporal change in a continuous variable: Example of HbA1c in patients with diabetes.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec227868f848f917344aa9be6894e7b0"><gtr:id>ec227868f848f917344aa9be6894e7b0</gtr:id><gtr:otherNames>Sheppard T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>5a2fda778b5039.71896881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85CDC81D-C123-45E9-ADAF-2390488431E2</gtr:id><gtr:title>The safety of biologic therapies in RA-associated interstitial lung disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>54595d28e4de93.21222374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2429DE6D-346C-4026-96ED-75E4D75AB8C8</gtr:id><gtr:title>Quantifying the longitudinal value of healthcare record collections for pharmacoepidemiology.</gtr:title><gtr:parentPublicationTitle>AMIA ... Annual Symposium proceedings. AMIA Symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4e3437b92767d45591fd60fb5819eae"><gtr:id>b4e3437b92767d45591fd60fb5819eae</gtr:id><gtr:otherNames>Sperrin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1559-4076</gtr:issn><gtr:outcomeId>pm_13869_29_22195193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00AFC9AF-C3C6-4717-BF87-A7505548F0D0</gtr:id><gtr:title>Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1fb87fcd35e0f57e8cbc96ade3f7db3"><gtr:id>d1fb87fcd35e0f57e8cbc96ade3f7db3</gtr:id><gtr:otherNames>Dixon WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_22851467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1710AEF6-B396-4DB3-AFE9-4A0B9A1C2ED9</gtr:id><gtr:title>Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>European journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bae0e95d8ad25d0dbffb5c07abb21bc"><gtr:id>8bae0e95d8ad25d0dbffb5c07abb21bc</gtr:id><gtr:otherNames>Movahedi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0393-2990</gtr:issn><gtr:outcomeId>585d32d4731c07.17585020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>182CE149-626C-4BCE-B5D9-F2A397997E3D</gtr:id><gtr:title>Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b554ef5cd2847f00de29f2ad057a4d05"><gtr:id>b554ef5cd2847f00de29f2ad057a4d05</gtr:id><gtr:otherNames>Zavada J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>doi_13869_013_204102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AD10BD8-380B-4135-8EC1-42E599A8A1CF</gtr:id><gtr:title>Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>pm_13869_29_23238979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECEBA9A8-98BE-4B06-B3DD-86289182F29E</gtr:id><gtr:title>Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/992b8e47d199294a5c50d2319860bada"><gtr:id>992b8e47d199294a5c50d2319860bada</gtr:id><gtr:otherNames>Davies R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_23076071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6A9B505-3BC4-4186-940A-77AE34D59806</gtr:id><gtr:title>Is anti-TNF therapy safer than previously thought?</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5f7f996170128bc8bbefc87ec0be8d"><gtr:id>9a5f7f996170128bc8bbefc87ec0be8d</gtr:id><gtr:otherNames>Dixon W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>pm_13869_29_22056396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32FC10B6-4C92-4302-8E15-F857494F6AFF</gtr:id><gtr:title>A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patients.</gtr:title><gtr:parentPublicationTitle>Journal of biopharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c341e02ebd02bc4c15e094ec20c89d4"><gtr:id>5c341e02ebd02bc4c15e094ec20c89d4</gtr:id><gtr:otherNames>Fu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1054-3406</gtr:issn><gtr:outcomeId>doi_13869_011_616973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7614C93-A723-453F-BABE-C5B85B2167A2</gtr:id><gtr:title>The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1fb87fcd35e0f57e8cbc96ade3f7db3"><gtr:id>d1fb87fcd35e0f57e8cbc96ade3f7db3</gtr:id><gtr:otherNames>Dixon WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>jBXZvBU81it</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1633692C-D255-4C77-B9BB-532B395088ED</gtr:id><gtr:title>Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bae0e95d8ad25d0dbffb5c07abb21bc"><gtr:id>8bae0e95d8ad25d0dbffb5c07abb21bc</gtr:id><gtr:otherNames>Movahedi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>56cb7e3d1cd2c4.89765882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64C9AABA-EF2A-429E-9C08-144A5DF4416B</gtr:id><gtr:title>Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52127935d746c82886e7c84ce28498cc"><gtr:id>52127935d746c82886e7c84ce28498cc</gtr:id><gtr:otherNames>Lahiri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1521-6942</gtr:issn><gtr:outcomeId>5675eb619b676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FD8A36A-9AA4-4F11-AD8E-95B390F9FABB</gtr:id><gtr:title>Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>doi_13869_pj_2013_26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7CC6ECF-2A37-46BB-953E-8613E81F806B</gtr:id><gtr:title>Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/714cf86530a1ae040bf0f71497a070cd"><gtr:id>714cf86530a1ae040bf0f71497a070cd</gtr:id><gtr:otherNames>Saketkoo LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>56cb7e3e67af41.01211051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61269FEC-6BB4-469C-8AF4-8E6530019C23</gtr:id><gtr:title>Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98552430a8c6a655baffc9011159e861"><gtr:id>98552430a8c6a655baffc9011159e861</gtr:id><gtr:otherNames>Zhou SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d3e66a98cd9.74938632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36CD5829-9D42-48AC-BBFA-A693BAE6D0EE</gtr:id><gtr:title>The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd89c3abad19c0472cdedb8fed78261b"><gtr:id>dd89c3abad19c0472cdedb8fed78261b</gtr:id><gtr:otherNames>Galloway JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>pm_13869_29_21489973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8E348C2-E16A-4328-BB1F-2EAF817F34B3</gtr:id><gtr:title>Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1717db27fd10816abbc00d8237bba250"><gtr:id>1717db27fd10816abbc00d8237bba250</gtr:id><gtr:otherNames>Verstappen SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13869_29_23065733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91E8A82B-E440-45CE-9B3A-E747E4A51F0B</gtr:id><gtr:title>A review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis population.</gtr:title><gtr:parentPublicationTitle>Bone</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49af01a02e7d89c559fec62a623e1287"><gtr:id>49af01a02e7d89c559fec62a623e1287</gtr:id><gtr:otherNames>Robinson DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1873-2763</gtr:issn><gtr:outcomeId>585d68d8eaa673.50483984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B510D9A2-8293-48FB-BAC9-B40619568643</gtr:id><gtr:title>Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4730225cd8cb5c9d48a0addd7c18360"><gtr:id>a4730225cd8cb5c9d48a0addd7c18360</gtr:id><gtr:otherNames>Costello R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d508f57ee84.68077580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC00476A-C645-4A8D-8BBE-B00046EDC023</gtr:id><gtr:title>Dynamic consent: a possible solution to improve patient confidence and trust in how electronic patient records are used in medical research.</gtr:title><gtr:parentPublicationTitle>JMIR medical informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db90bea6afb57b3e338699dd2681fe92"><gtr:id>db90bea6afb57b3e338699dd2681fe92</gtr:id><gtr:otherNames>Williams H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>54595dd2907136.37758978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6336623F-01A5-48B2-BCFD-35B95ED02C7C</gtr:id><gtr:title>The Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8e571df0601bcdef6003f0de36363e7"><gtr:id>e8e571df0601bcdef6003f0de36363e7</gtr:id><gtr:otherNames>Black RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a735c42b32b74.69612853</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902272</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>